FindTrial
Sign In

Cardiovascular effects of esmolol alone and in combination with levosimendan during septic shock

Cardiovascular effects of esmolol alone and in combination with levosimendan during septic shock

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2012-003012-31-FR
Enrollment
Unknown
Registered
2015-09-23
Start date
Unknown
Completion date
Unknown
Last updated
2015-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 18.0 Level: PT Classification code 10040070 Term: Septic shock System Organ Class: 10021881 - Infections and infestations

Interventions

Trade Name: BREVIBLOC Pharmaceutical Form: Solution for injection Trade Name: SIMDAX Pharmaceutical Form: Solution for injection

Sponsors

DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: NO Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: NO

Design outcomes

Primary

MeasureTime frame
Main Objective: NO;Secondary Objective: No;Primary end point(s): NO;Timepoint(s) of evaluation of this end point: NO—

Secondary

MeasureTime frame
Timepoint(s) of evaluation of this end point: NO—

Countries

France

Contacts

Public ContactChef du BuCHU

Institut de recherche biomedicale des armées

celluleprojets@gmail.com33(0)169238101

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026